With an increasing number of COVID-19 vaccines becoming available, the end of the pandemic is now in sight, but even with efforts to scale up production the supply of vaccines will influence the speed of vaccination. As a result, careful vaccine allocation is needed to maximize social and economic benefits across the U.S. Multiple frameworks have recently been developed to guide vaccine allocation, including one led by our team at CRA and the Center for Global Health Innovation (CGHI) Vaccine Economics and Equity Group (VEEG).1 As we discuss in PM360, this new framework offers guidelines for COVID-19 vaccine allocation under conditions of scarcity that considers core public health and ethical principles in the context of optimal benefit to the U.S. economy.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...